Overview

---

There has been a considerable transformation in India in regard to being one of the major manufacturer and supplier of generic drugs, and it has been praised for the efforts it has made for being the pharmacy of the world. Investments in technological health solutions and adoption of information and communications technology is helping to advance patient care, reduce expenses, enhance transparency, increase productivity and develop novel treatments. 

The biopharmaceutical industry is also witnessing rapid advancements with AI's integration, especially in monoclonal antibodies (mAbs) and the broader drug development landscape. This event aims to delve into the transformative impact of AI, the evolving role of CROs and CDMOs, and the significance of the Biosecure Act in shaping the future of biopharma.

New technologies including AI, are accelerating the discovery and development of monoclonal antibodies (mAbs), reshaping biopharma production processes, and enhancing the therapeutic potential of mAbs for treating complex diseases such as cancer and autoimmune disorders. This event is bringing together industry experts and stakeholders to explore how AI is driving innovation across the biopharma sector, from drug discovery to clinical trials and regulatory compliance, while also discussing the strategic importance of the Biosecure Act in positioning India as a global biopharma hub.